ReviewCurrent neuropharmacology2026
Targeting Epigenetics in Ischemic Stroke: From Mechanisms to Therapeutics.
Review in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Ischemic stroke is the main cause of death and disability in human diseases worldwide. Due to the complexity of its pathophysiological mechanism, the treatment effect is not ideal. Epigenetics refers to the mechanisms of affecting gene function and expression by chemical modification or chromatin structure without changing the DNA sequence. The epigenetic network is mainly composed of various epigenetic modifying enzymes (such as DNA methyltransferase/demethylase, DNMT/tet, histone methyltransferase/demethylase, HMT/hdm, histone acetyltransferase/deacetylase hat/hdac) and non-coding RNAs with different functions. Epigenetic enzymes or non-coding RNAs can participate in the core pathophysiological processes after ischemic stroke, such as neuroinflammation, oxidative stress, and cell apoptosis, by regulating the activation or silencing of key gene transcription. Due to the regulatory role of epigenetic modifying enzymes and non-coding RNAs after ischemic stroke, targeted intervention of these epigenetic modifying enzymes and non-coding RNAs has been confirmed to improve the pathological process and neurological outcome after ischemia. Therefore, they are regarded as a series of therapeutic targets with great research and development potential. This study systematically reviewed the role and mechanism of DNA methylation, histone modification, and non-coding RNA in the pathological development of ischemic stroke, and discussed the research progress of related therapeutic drugs targeting these epigenetic modifying enzymes, in order to provide a theoretical basis and ideas for the development of new clinical diagnosis and treatment strategies for ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.